- Home
- WLYB vs IDYA Comparison
WLYB vs IDYA Comparison
Compare WLYB & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLYB
- IDYA
- Stock Information
- Founded
- WLYB 1807
- IDYA 2015
- Country
- WLYB United States
- IDYA United States
- Employees
- WLYB N/A
- IDYA N/A
- Industry
- WLYB Books
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- WLYB Consumer Discretionary
- IDYA Health Care
- Exchange
- WLYB Nasdaq
- IDYA Nasdaq
- Market Cap
- WLYB 2.1B
- IDYA 2.3B
- IPO Year
- WLYB N/A
- IDYA 2019
- Fundamental
- Price
- WLYB $42.11
- IDYA $24.44
- Analyst Decision
- WLYB
- IDYA Buy
- Analyst Count
- WLYB 0
- IDYA 14
- Target Price
- WLYB N/A
- IDYA $47.75
- AVG Volume (30 Days)
- WLYB 238.0
- IDYA 1.2M
- Earning Date
- WLYB 09-04-2025
- IDYA 11-03-2025
- Dividend Yield
- WLYB 3.34%
- IDYA N/A
- EPS Growth
- WLYB N/A
- IDYA N/A
- EPS
- WLYB 1.78
- IDYA N/A
- Revenue
- WLYB $1,670,600,000.00
- IDYA $7,000,000.00
- Revenue This Year
- WLYB $1.45
- IDYA $62.30
- Revenue Next Year
- WLYB $2.70
- IDYA $285.58
- P/E Ratio
- WLYB $23.00
- IDYA N/A
- Revenue Growth
- WLYB N/A
- IDYA N/A
- 52 Week Low
- WLYB $37.27
- IDYA $13.45
- 52 Week High
- WLYB $52.90
- IDYA $37.19
- Technical
- Relative Strength Index (RSI)
- WLYB 67.63
- IDYA 49.04
- Support Level
- WLYB $39.63
- IDYA $24.24
- Resistance Level
- WLYB $42.54
- IDYA $25.49
- Average True Range (ATR)
- WLYB 0.01
- IDYA 1.35
- MACD
- WLYB 0.22
- IDYA -0.15
- Stochastic Oscillator
- WLYB 84.01
- IDYA 27.13
About WLYB John Wiley & Sons Inc.
John Wiley & Sons Inc is one of the world's greatest publishers and a trusted leader in research and learning. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.